Application of PI3K (Phosphatidylinositol 3-Kinase) inhibitor to preparation of medicine for treating related diseases of thrombocytopenia

A technique for thrombocytopenia and platelets, which is used in the field of PI3K inhibitors to prepare medicines for diseases related to decreased platelet counts, and can solve problems such as shortening the lifespan of platelets

Active Publication Date: 2018-07-24
SUZHOU UNIV
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Technical problem to be solved: The pathogenesis of thrombocytopenia caused by different etiologies is due to the shortened lifespan of platelets caused by apoptosis and activation, and is cleared

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PI3K (Phosphatidylinositol 3-Kinase) inhibitor to preparation of medicine for treating related diseases of thrombocytopenia
  • Application of PI3K (Phosphatidylinositol 3-Kinase) inhibitor to preparation of medicine for treating related diseases of thrombocytopenia
  • Application of PI3K (Phosphatidylinositol 3-Kinase) inhibitor to preparation of medicine for treating related diseases of thrombocytopenia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0033] 1. Experimental mice

[0034] All experimental animal-related welfare is strictly implemented in accordance with the "Regulations on the Administration of Experimental Animals" of the People's Republic of China. Animal experiments were approved by the Medical Ethics Committee of Soochow University.

[0035] 2. Wash platelets

[0036] Healthy adult volunteers collected blood from the median vein of the elbow. Blood donors have no bad living habits such as smoking and drinking, and have not taken any drugs that affect platelet function within 2 weeks before blood donation. Female blood donors are not menstruating. All blood donors gave informed consent and signed the agreement. The experimental protocol was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University and complied with the Declaration of Helsinki.

[0037]A certain amount of venous blood was drawn from a healthy person and anticoagulated with 1 / 7 volume of Acid-citratedextro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of PI3K (Phosphatidylinositol 3-Kinase) inhibitor to preparation of a medicine for treating related diseases of thrombocytopenia. Firstly, an experiment explores the effect of PI3K in a process of clearing platelets and proves that activation and apoptosis of the platelets of patients with the thrombocytopenia occur. An anti-Ibalpha antibody induces PI3K activation and Akt is activated after the PI3K is activated; the Akt is used for mediating the activation and apoptosis of the platelets. The Akt is used for regulating and controlling the apoptosis of the platelets through phosphodiesterase mediated protein kinase A. PS (Phosphatidylserine) is exposed after the apoptosis and activation of the platelets and is phagocytized by macrophages of liver. The activation of the PI3K is inhibited, the activation and apoptosis of the platelets are inhibited and the clearance of the platelets is stopped; the PI3K inhibitor can be used for treating the related diseases of platelet quantity changes and the thrombocytopenia in peripheral circulating blood is inhibited, so that the inhibitor has a potential of being prepared into novel platelet protection medicines and medicines for treating the thrombocytopenia, and extremely good scientific research and economic value.

Description

technical field [0001] The invention belongs to the field of platelet-related drugs, and in particular relates to the use of PI3K inhibitors in the preparation of drugs for treating diseases related to platelet count reduction. Background technique [0002] Thrombocytopenia is a common clinical symptom, which can lead to serious consequences of hemorrhage and even fatal internal hemorrhage. Thrombocytopenia-related diseases include immune thrombocytopenia, infection-induced thrombocytopenia, secondary thrombocytopenia, drug-induced thrombocytopenia, thrombocytopenia deficiency, non-immune thrombocytopenia, and decreased platelet production diseases, diseases caused by increased platelet destruction, or thrombotic thrombocytopenic purpura, etc. The pathogenesis of thrombocytopenia caused by these different etiologies is due to the shortened lifespan of platelets caused by apoptosis and activation, and the platelets are eliminated. Immune Thrombocytopenia (ITP) is a common a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61P7/04
CPCA61K45/00
Inventor 戴克胜
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap